Not exact matches
Also at GSK, she served as Vice President
of Global Regulatory Affairs for
Oncology, in addition to providing regulatory leadership on a
number of innovation and operational excellence initiatives.
At US
Oncology, Bruce served in a
number of senior executive roles, including Chief Financial Officer, President, Chief Executive Officer and Chairman
of the Board.
These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount
of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability
of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction
of generic versions
of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect
of lowering prices or reducing the
number of insured patients; the possibility
of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels
of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits
of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages
of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology /
oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development
of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate
of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).
The study, was reported Feb 13 to the 5th International Conference on Innovative Approaches in Head and Neck
Oncology (ICHNO) will reduce significantly the
number of HNSCC patients who currently undergo selective neck dissection (SND), a procedure which involves removing a group
of lymph nodes from the neck in order to try to eradicate those which may have been reached by the cancer.
Principal Investigator John Morris, MD, clinical co-leader
of the Molecular Therapeutics and Diagnosis Program for the CCC, co-leader
of the UC Cancer Institute's Comprehensive Lung Cancer Program, professor in the division
of hematology
oncology at the UC College
of Medicine and UC Health medical oncologist, says a
number of antitumor vaccines have shown promise for causing immune responses against tumor antigens to improve patient outcomes.
A
number of immuno -
oncology therapies on the horizon tackle this problem in novel ways.
These data, published in the Journal
of Thoracic
Oncology, the official journal
of the International Association for the Study
of Lung Cancer, suggest that these elevated
numbers of malignant mesothelioma cases are linked to environmental exposure
of carcinogenic mineral fibers.
Researchers from Sanford Health and Chronix Biomedical today announced that results from a pilot study demonstrating the utility
of a new cancer panel to detect previously undetected viral and cancer mutations are to be reported in a poster presentation titled «Detection
of novel HPV mutations and chromosomal
number imbalance (CNI) in oropharyngeal and laryngeal cancer using next - generation sequencing (NGS)» at the American Society
of Clinical
Oncology Annual Meeting (ASCO 2014) being held from May 30 through June 3, 2014 in Chicago.
Susan Galbraith, head
of the
oncology innovative medicines unit at AstraZeneca, said: «Lung cancer is still the leading cancer killer, and we are working on a
number of potential treatment options that could provide patients with a better chance
of beating the disease.
«One promising strategy to reduce the
number of people affected by pancreatic cancer is to identify and treat premalignant pancreatic lesions,» said first author Jennifer Permuth - Wey, Ph.D., M.S., assistant member in the Departments
of Cancer Epidemiology and Gastrointestinal
Oncology at Moffitt.
In a presentation
of early clinical trial data to the 20th Annual Scientific Meeting
of the Society for Neuro -
Oncology, physician scientists from the University
of New Mexico Comprehensive Cancer Center reported that a large
number of study participants responded well to the drug combination.
Researchers from the University's Department
of Oncology and Metabolism analysed 462 scientific studies and found appetite ratings failed to correspond with energy intake — the
number of calories consumed — in the majority
of studies.
During the years, a
number of renovations have been made and services added including Radiation
Oncology, Computer - Assisted Minimally - Invasive Orthopaedic Surgery, Digital Mammography, Fixed Cardiac Catheterization, MRI, Inpatient Dialysis, 24 - hour Emergency Services, Cardio - pulmonary; Laboratory; Diagnostic Imaging and Physical Therapy.
Through the generosity
of the ECCO 2018 European Cancer Summit partners, a limited
number of grants will be available for Patient Advocates,
Oncology Nurses and Young
Oncology Professionals based in Europe.
Dr. Gaspar serves on a
number of national boards and committees including the Southwest
Oncology Group (SWOG), American Society
of Clinical
Oncology (ASCO), Radiation Therapy
Oncology Group (RTOG), American Society
of Radiation
Oncology (ASTRO), and the American College
of Radiology (ACR).
While integrated models
of palliative care in
oncology clinics are critical to beginning palliative care early in the course
of disease, they may miss important, vulnerable populations who use the ED in disproportionate
numbers.
The expansion increases the
number of acute care
oncology inpatient beds from 113 to 148 and adds a new
oncology intensive care unit.
In order to provide your pet with comprehensive care, members
of our veterinary team have been highly - trained in a
number of specialties, including acupuncture, cardiology,
oncology, neurology, surgery, internal medicine and more.
The
number one natural cause
of deaths in older pets is cancer.Source: Veterinary
Oncology & Hematology Center
Clinicians in the AHTs Clinical
Oncology Unit have encountered a
number of young Shar Pei with unusually aggressive mast cell tumours, and previous reports in veterinary medical journals describe an increased incidence
of mast cell tumours in Shar Pei, with aggressive mast cell tumours more common in Shar Pei under 2 years
of age.
Graduate training in translational research may be pursued in a
number of fields related to clinical and basic sciences, including anesthesiology and pain management, behavior, cardiology, clinical epidemiology and population medicine, dentistry, diagnostic imaging (radiology), large animal internal medicine, large animal surgery,
oncology, ophthalmology, production medicine (ruminant and swine), radiation
oncology, small animal internal medicine, small animal surgery, and theriogenology.
A
number of funded or partially funded clinical trials are ongoing through the Clinical
Oncology Service.
Atherton Godfrey Solicitors has a highly rated clinical negligence practice based in Doncaster, which handles claims involving birth injury, misdiagnosis,
oncology, GP care and fatality, and is one
of a small
number of local firms with the ability to handle birth injury cases under contract with the Legal Aid Agency.
According to a special research paper on the prevalence
of cancer in India which was printed in Lancet
Oncology journal, by 2035, these
numbers may increase substantially and 17 lakh fresh patients may be diagnosed with cancer, with about 12 lakh people dying from it every year.
Chemotherapy technicians might experience excellent job prospects as indicated by statistics from the American Society
of Clinical
Oncology, which predicted a 48 % increase in the
number of cancer cases from 2007 - 2020.
Lead at all levels; in use
of lean tools and techniques to drive improvements Coached all levels
of leaders from managers to executives on lean and strategic implementation Certified TWI - JI, Facilitative Leadership, trainer
of Greenbelt, Toyota Kata, and many more Lean philosophies Facilitated Kaizen events, Values Stream Analysis, Vertical Value Streams Ensure clear metrics are established and collected for each event and align with organizational goals and metrics Successfully built relationships and refined processes within
Oncology, Center for Rehab and Wellness, Surgical Services, Meditech Standardization, Human Resources, Corporate Compliance, and Strategic Services Worked on processes that cross multiple areas
of reporting as well as across different tax ID
numbers.